Nachrichten zur Agios Pharmaceuticals Inc. Aktie

Form 8-K AGIOS PHARMACEUTICALS, For: May 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff

7 Analysts Have This to Say About Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter: Latest Ratings for AGIO …

Agios Announces Evolution of Research Organization

– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to…

Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K AGIOS PHARMACEUTICALS, For: May 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals GAAP EPS of -$1.74 beats by $0.07, revenue of $0.83M misses by $1.88M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K AGIOS PHARMACEUTICALS, For: Apr 25

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis…

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog....…

Form 8-K AGIOS PHARMACEUTICALS, For: Feb 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Q4 2021 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals With FDA Approval Is A Buy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

What 4 Analyst Ratings Have To Say About Agios Pharmaceuticals

Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings: Latest Ratings for AGIO …

Insiderhandel: Principal Accounting Officer verkauft Aktien von Agios Pharmaceuticals im Wert von 7.179$

Washburn, Theodore James Jr. - Vorstand - Tag der Transaktion: 2022-02-16...…

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

Agios Pharmaceuticals (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder....…

Agios Pyrukynd for rare blood disorder gets US FDA approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless…

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios

Heres a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyxs ALS Treatment Regulatory…

Insiderhandel: Principal Accounting Officer verkauft Aktien von Agios Pharmaceuticals im Wert von 15.750$

Washburn, Theodore James Jr. - Vorstand - Tag der Transaktion: 2022-02-14...…

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains…

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Form 8-K AGIOS PHARMACEUTICALS, For: Jan 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden

Agios Pharmaceuticals Inc (NASDAQ: AGIO) read more...…

Agios presents mitapivat long-term data in PK deficiency at ASH 2021

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Appoints Richa Poddar as Chief Commercial Officer

Darrin Miles to Depart Agios to Pursue a Chief Executive Officer Opportunity Darrin Miles to Depart Agios to Pursue a…

Global Porphyria Pipeline Market Research Report 2021 Featuring Agios Pharma, Alnylam Pharma, Clinuvel Pharma, Mitsubishi Tanabe, Moderna, Palatin Technologies, & Recordati Rare Diseases

DUBLIN, Nov. 15, 2021 /PRNewswire/ -- The "Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added…

CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search…

Agios Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals, inc (AGIO) Q3 2021 Earnings Call Transcript

AGIO earnings call for the period ending September 30, 2021....…

Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3

Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the…

Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do…

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set…

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios To Present at September Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --...…

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals, inc (AGIO) Q2 2021 Earnings Call Transcript

AGIO earnings call for the period ending June 30, 2021....…

Agios Pharmaceuticals EPS misses by $0.12

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase…

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…